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a b s t r a c t
Methotrexate is a widely used cytostatic in chemotherapy cocktails for the treatment of cancer but is
associated with cognitive impairment. Previous animal studies indicated that methorexate decreases
hippocampal cell proliferation, which might contribute to the observed cognitive impairment. However,
clinical studies have shown that cognitive impairment can also be noticed in some cancer patients before
any systemic treatment is initiated. We aim in the present study to discern whether hippocampal cell
proliferation is negatively affected by tumor growth and if the presence of a tumor ampliﬁes the effects
of methotrexate.
Buffalo rats were subcutaneously injected with PBS or Morris Hepatoma 7777 cells to induce a tumor.
Twoweeks after this injection the animals received an intraperitoneal injection ofmethotrexate or saline.
Three weeks later hippocampal cell proliferation was quantiﬁed using immunohistochemical staining.
Treatment with Morris Hepatoma 7777 cells decreased the number of proliferating cells as compared
to control animals. An overall tumor effect was absent mainly because methotrexate treatment signiﬁ-
cantly decreased cell proliferation with no differences between animals with or without a tumor. Neither
methotrexate nor the tumor induced pica behavior.
These ﬁndings indicate that although the presence of a tumor reduces hippocampal cell proliferation
it does not affect the negative effect of methotrexate on this plasticity marker. Since sickness behavior is
not induced by methotrexate or tumor presence it does not play a role in the development of cognitive
deﬁcits. This study further indicates that the effects ofmethotrexate on brain and behavior can be studied
in healthy animals.
. IntroductionChemotherapy is frequently used as adjuvant treatment strat-
gy for cancer and is associated with cognitive impairment in
art of the patients [3,28]. A number of animal studies have
een carried out to explore the action of cytostatics on brain and
ehavior, and in these studies methotrexate (MTX), a cytostatic
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agent used in an adjuvant chemotherapy cocktail, is often explored
[6,14,18,21,22,29]. Our studies have shown thatMTXhas a negative
effect on cognitive behavior and hippocampal cell proliferation,
which was observed already shortly after treatment and lasted
for several weeks [21,22]. This cell proliferation is part of the
process of neurogenesis, which is thought to play an important
role in learning and memory [8,12,13]. Therefore, a decrease in
hippocampal cell proliferation may contribute to the cognitive
impairment described above.
In animal models, the effect of cytostatics on cognitive behav-
ior is generally examined in healthy animals, which diverges from
the clinical situation. Furthermore, there are indications that a sub-
group of cancer patients suffers from cognitive impairment before
any systemic treatment is initiated [9,26,27]. There are currently
no clear indications which neural principles might be involved in
this impairment. Since we have shown in previous studies that

































































gain in the animals treated with Morris Hepatoma 7777 indicates
anorexia cachexia. After the onset of anorexia cachexia, which was
also determined by a consistent reduction in food intake, the ani-
mals received MTX or saline.R. Seigers et al. / Brain Rese
ion in healthy rats [21,22], one of the aims of the present study
as to validate our animal model by studying the effects of MTX
n a tumor model. With this study, we tried to answer a number
f questions: is the presence of a tumor negatively affecting hip-
ocampal cell proliferation; is theeffect ofMTXon thisproliferation
ctually potentiated by the tumor; and does MTX and/or tumor
resence induce sickness behavior in tumor-bearing animals. Sick-
ess behavior was studied since it is associated with decreased
ognition [17]. Induction of proinﬂammatory cytokines can induce
ickness behavior and both chemotherapeutic drugs and cancer
achexia are related to peripheral cytokine release [17,24].
We used an animal model of hepatoma, in which Buffalo rats
ere subcutaneously injected with Morris Hepatoma 7777 cells.
fter the appearance of cancer cachexia the animals were treated
ith a single, intraperitoneal injection of MTX. Sickness behavior
as measured by the presence of pica behavior, which is the con-
umption of non-nutritive substances [2]. Cell proliferation was
tudied by measuring Ki-67 positive cells in hippocampal slices.
. Methods
.1. General
Twenty-eight adult (3 months of age) male Buffalo rats (average body weight
t the start of the experiment 319g±2.8 SEM) were obtained from Harlan (Zeist,
he Netherlands). The animals were housed individually in clear Plexiglas cages on
layer of wood shavings with a ﬁxed 12:12h light:dark cycle (with lights on at
8.00 a.m.), and food and water ad libitum. Four experimental groups were used
PBS/saline, PBS/MTX, Morris Hepatoma 7777/saline, Morris Hepatoma 7777/MTX)
ach consistingof 7 rats andexperiments started3weeks after arrival of the animals.
he experiment was approved by the Animal Experimentation Committee of the
niversity of Groningen and complied with the EC Council Directives.
Morris Hepatoma 7777 cells were obtained from LGC Ltd. (Middlesex, Eng-
and) and grown according to the distributor’s recommendations in standardDMEM
edium, with 5% fetal calf serum, 4.5% glucose, at 37 ◦C, and 10% CO2. The cells were
arvested, centrifuged and transferred into sterile PBS and injected subcutaneously
etween the shoulder blades during a short-lasting anesthesia of isoﬂurane mixed
ith normal air. Cells were injected in a dosage of 7.5–10 million cells dissolved
n 1ml PBS per animal and the injection puncture was closed with a single suture.
ontrol animals were injected according to the same procedure with PBS.
Body weight gain and food intake were measured daily and average food intake
as calculated from day 2 until day 8 after the injection. MTX or saline was injected
hen the animal consumed 80% or less of its average food intake for 2 consecutive
ays. Half of the tumor-bearing animals and half of the control animals received an
ntraperitoneal injection of MTX (100mg/kg, 100mg/ml, Pharmachemie BV, Haar-
em, the Netherlands), the remaining animals received saline. After the injection,
nimals received intraperitoneal injections of calcium leucovorin (10mg/ml, Phar-
achemie BV, Haarlem, the Netherlands), which is clinically used as a so-called
escue therapy in combination with the cytotoxic agent. Pilot studies revealed that
eucovorin itself does not have an effect on cell proliferation and that high-doseMTX
ithout leucovorin is lethal due to severe diarrhea andweight loss. This rescue ther-
py is based on the fact that leucovorin is a tetrahydrofolate (THFA) that does not
equire activation by THFA reductase. Tetrahydrofolate is a cofactor in DNA syn-
hesis; MTX is an inhibitor of the enzyme THFA reductase and depletes the pool of
etrahydrofolates [7,10]. The rescue therapy of leucovorin was administered in a
rotocol similar to the application in patients. Eighteen hours after the injection of
TX, leucovorin was administered in a concentration that was 8% of the injected
TX dosage; at 26, 42, and 50h the administered concentration was reduced to 4%.
.2. Pica behavior
Kaolin pellets were made according to a protocol of Vera et al. [25]. In brief,
aolin powder, gum Arabic, and carmine (all substances were purchased from
igma Aldrich, Lyon, France) were mixed in a proportion of 98.5%, 1%, and 0.5%
espectively. Carmine was added to the mixture because it colors faeces pink.
istilled water was added to the mixture to create a thick pasta which was molded
nto pellets and air dried for 48h at room temperature. The pellets were placed in
he cage directly after the injection of MTX or saline in cachexic and control animals
or 1 week to see whether MTX or anorexia cachexia causes pica behavior. The pink
aeces was removed from the cage daily and weighed, to achieve an estimation of
he pica behavior.
.3. Effect of MTX and tumor growth on hippocampal cell proliferation
The animals were sacriﬁced 3 weeks after the injection with saline or MTX
hrough transcardialperfusionwithsaline followedby4%paraformaldehydeand theulletin 81 (2010) 472–476 473
tumorswere removed andweighed. Brainswere removed andplaced in 30% sucrose
solution at 4 ◦C. Microtome sections of the hippocampus (30m) were stored at
−20 ◦C in 30% ethyleneglycol/30% glucose in PBS solution until immunohistochem-
ical staining.
From the serial sections, every sixth section from each animal was selected
and immunocytochemically stained for Ki-67 using a slightly adapted standard
protocol [11]. In brief, free-ﬂoating sections were pre-treated with 0.4% H2O2 for
30min, to stop endogenous peroxidase activity. Non-speciﬁc binding of immunore-
agents was blocked with 3% normal goat serum (Zymed, San Francisco, CA, USA).
Subsequently, sections were incubated with mouse-anti-Ki-67 (1:200, Novocastra,
Newcastle upon Tyne, UK), for 48h at 4 ◦C. After a second blocking step, sections
were incubated with a biotinylated secondary antibody (1:400, goat-anti-mouse,
Jackson, Wet Grove, PA, USA) for 2h at room temperature. This was followed by
incubation in anavidinbiotinylatedperoxidase complex (1:400, ABCEliteKit, Vector
Laboratories, Burlingame, CA, USA). Labeled cells were visualized with 0.15mg/ml
diaminobenzidine and 0.003% H2O2 solution.
After mounting the sections onto glass slides for microscopic analysis, sections
were counterstained with a Mayer-haematox solution for 30 s. Counting of Ki-67
positive cells in both hemispheres of the dentate gyrus was performed under a light
microscopewith amagniﬁcation of 400×. Countingwas performed in the subgranu-
lar layer of the dentate gyrus and counts in both blades were summed. The border of
the area thatwas quantiﬁedwas deﬁned as the subgranular layer having a thickness
of two cell diameters. All cells were counted in the subgranular layer of the dentate
gyrus from top to bottom of the 30m thick sections. Because every sixth section
of the brain was stained, with a total of 18 slices per animal, the amount of positive
cells was multiplied by 6 to get the estimated total amount of Ki-67 positive cells in
the hippocampus.
2.4. Statistics
Body weight and food intake were analyzed using two-way repeated measure
ANOVA. Signiﬁcant differences between the different days for body weight and
food intake was measured with an independent-sample T-test when the two-way
repeated measure ANOVA was signiﬁcant. Light-microscopic counts of Ki-67 posi-
tive cells were analyzed using two-way ANOVA. In all tests PBS/Morris Hepatoma
7777and saline/MTXwereusedasbetween-subject variables. For all statistical tests,
a probability value less than 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. The effect of Morris Hepatoma 7777 cells and MTX on body
weight gain
Body weight of all animals was measured daily and expressed
as percentage of the body weight on the day of the injection with
PBS orMorris Hepatoma7777 in Fig. 1. The decrease in bodyweightFig. 1. Body weight gain after treatment with PBS (©) or Morris Hepatoma 7777
(). The decrease in body weight gain in animals treated with Morris Hepatoma
7777 indicates the onset of anorexia cachexia.
474 R. Seigers et al. / Brain Research Bulletin 81 (2010) 472–476
Fig. 2. Body weight gain after intraperitoneal administration of saline or MTX. The
different groups are PBS/saline (©), PBS/MTX ( ), Morris Hepatoma 7777/saline
( ), andMorrisHepatoma7777/MTX (). Bodyweight before the injection (givenon
day 0) is expressed as 100%; bars represent standard error of themean. Amain effect








































Fig. 3. Food intake after intraperitoneal administration of saline or MTX. The dif-
ferent groups are PBS/saline (©), PBS/MTX ( ), Morris Hepatoma 7777/saline ( ),
andMorrisHepatoma7777/MTX (). Data are representedasmean± standardof the
mean. A main effect was found between treatment with PBS and Morris Hepatomareatment with saline and MTX. No interaction effect between PBS/Morris Hep-
toma7777and saline/MTXwas found. The * and ˆ represent a signiﬁcant difference
etween animals treated with PBS or Morris Hepatoma 7777, and animals treated
ith saline or MTX respectively.
Body weight of all animals after treatment with MTX or saline
as measured daily and expressed as percentage of the body
eight on the day of the injection. Fig. 2 shows that body weight
ecreased in animals treated with MTX. Animals treated with
BS/MTX started to regain body weight from day 5, whereas the
umor-bearing animals treated with MTX did not. The body weight
n tumor-bearing animals treated with saline also decreased dur-
ng the experiment. A main effect was found between treatment
ith PBS and Morris Hepatoma 7777 (F(1.24) =50.737, P<0.001).
hen analyzed with an independent-sample T-test a signiﬁcant
ifference was seen between animals treated with PBS and Mor-
is Hepatoma 7777 from day 1 until day 20 (P<0.05), with the
xception of days 3 and 4 which was caused by a decrease in
ody weight gain due to MTX treatment. A main effect was also
ound between treatment with saline and MTX (F(1,24) =10.593,
< 0.005). When analyzed with an independent-sample T-test a
igniﬁcant difference was seen between animals treated with
aline and MTX from day 1 until day 9 (P<0.05). No interac-
ion effect between PBS/Morris Hepatoma 7777 and saline/MTX
as found.
.2. The effect of Morris Hepatoma 7777 cells and MTX on food
ntake
Food intake of all animals was measured daily following MTX
r saline administration and is shown in Fig. 3. The animals treated
ith MTX decreased food intake directly after the injection. How-
ver, in animals treated with PBS/MTX food intake reached the
evel of the animals treated with PBS/saline after day 6, whereas
ood intake of animals treated with Morris Hepatoma 7777/MTX
emained at the level of the animals treated with Morris Hepatoma
777/saline. A main effect was found between treatment with PBS
ndMorris Hepatoma 7777 (F(1,24) =39.463, P<0.001).When ana-
yzed with an independent-sample T-test a signiﬁcant difference
as seen between animals treated with PBS and Morris Hepatoma
777 from day 0 until day 20 (P<0.05), with the exception of days
and 4 which was caused by a decrease in body weight gain due to
TX treatment. A main effect was also found between treatment
ith saline andMTX (F(1,24) =4.402, P<0.05).When analyzedwith7777 and between treatment with saline and MTX. No interaction effect between
PBS/Morris Hepatoma 7777 and saline/MTX was found. The * and ˆ represent a sig-
niﬁcant difference between animals treatedwith PBS orMorris Hepatoma7777, and
animals treated with saline or MTX respectively.
an independent-sample T-test a signiﬁcant difference was seen
between animals treated with saline and MTX from day 1 until day
5 (P<0.05). No interaction effect between PBS/Morris Hepatoma
7777 and saline/MTX was found.
3.3. Pica behavior
Kaolin pellets were placed in the cage of the animals directly
after the injection with MTX or saline to study the effect on pica
behavior as a measure of sickness behavior. Carmine was added
to the pellets, so the consumption of kaolin could be measured by
the presence of pink faeces. The amount of pink faeces was low
in all groups (average amount for all groups together 0.3 g±0.7
SEM), with no signiﬁcant differences between the groups (data not
shown).
3.4. Effect of MTX and tumor growth on hippocampal cell
proliferation
Three weeks after treatment with MTX, the animals were sac-
riﬁced and the tumors were removed and weighed. There was no
signiﬁcant difference in the weight of the tumor between saline
treated animals and animals treated with MTX. The relative tumor
weight per total body weight was 1.65%±0.59 SEM for animals
treated with saline, and 1.90%±0.76 SEM for animals treated with
MTX. The absolute tumor weight was 5.26±1.77 SEM for animals
treated with saline, and 5.75±2.28 SEM for animals treated with
MTX.
Ki-67 positive cells in microtome sections of the hippocampus
were visualized and counted (Fig. 4). The total number of Ki-67
positive cells were 1114.5±304.5 SEM for animals treated with
PBS/saline; 470.4±106.2 SEM for animals treated with PBS/MTX;
752.4±95.3 SEM for animals treated with Morris Hepatoma
7777/saline; and440.4±164.8 SEMfor animals treatedwithMorris
Hepatoma 7777/MTX. A main effect was found between treatment
with saline and MTX (F(1,24) =10.117, P<0.01). No main effect was
found between treatment with PBS and Morris Hepatoma 7777.
However, this is most likely the result from the large decrease
in hippocampal cell proliferation after MTX treatment which may
indicate a ceiling effect. When compared individually with a one-
R. Seigers et al. / Brain Research B
Fig. 4. Total number of Ki-67 positive cells in the hippocampus of animals treated
with PBS/saline (), PBS/MTX ( ), Morris Hepatoma 7777/saline ( ), and Morris
Hepatoma 7777/MTX (). Data are represented as mean with standard error of the
mean. A main effect was found between treatment with saline and MTX (repre-
sented with *). No main effect was found between treatment with PBS and Morris
Hepatoma 7777. Since this is mainly caused by the fact that MTX treatment causes







































soticed that Morris Hepatoma 7777 administration did cause a signiﬁcant inhi-
ition of hippocampal cell proliferation when compared to the PBS/saline control
roup. No interaction effect between PBS/Morris Hepatoma 7777 and saline/MTX
as found.
ay ANOVA, a signiﬁcant effect was seen between the different
roups (F(3,18) =4.036, P<0.05). Test for contrast revealed a signif-
cant different between animals treatedwith PBS/saline andMorris
epatoma 7777/saline (P<0.001). No interaction effect between
BS/Morris Hepatoma 7777 and saline/MTX was found.
. Discussion
We explored in this paper the effect of MTX on hippocampal
ell proliferation in a tumor model. MTX signiﬁcantly reduced the
otal number of Ki-67 positive cells in the hippocampus compared
o control animals, indicating a decreased amount of proliferating
ells. The negative effect of MTX on hippocampal cell proliferation
as expected since our previous studies also showed a decrease in
he total number of Ki-67 positive cells after treatment with MTX
21,22].MTX is a dihydrofolate reductase inhibitor andhas its effect
n cell death by inhibiting the conversion of folic acid into tetrahy-
rofolate thereby inhibiting the synthesis of purine and thymidine
15]. In case the effects of MTX are mediated by a direct action of
TX in the brain, a sufﬁcient amount of MTX penetrates the brain
o have this effect on hippocampal cell proliferation as well.
Cognitive impairment is not only described after treatmentwith
hemotherapy [1,3,16,20,23,28], but also in the period between
iagnosis and systemic treatment [9,26,27]. The presence of a
umor in our study did appear to decrease the number of prolifer-
ting cells in the hippocampus, suggesting that this may contribute
o the cognitive impairment observed in cancer patients before
ny treatment is initiated. In patients additional explanations for
his early cognitive impairment can be found in diagnosis related
motional stress, or DNA damage and/or deﬁciencies in DNA repair
echanisms [9,26,27] with the latter two being linked both to the
evelopment of cancer and neurodegenerative disorders. The pres-
nce of a tumor, however, did not further enhance the negative
ffects of MTX on hippocampal proliferation. This ﬁnding indicates
hat the effects of adjuvant chemotherapy onhippocampal cell pro-
iferation as observed in healthy animals can be extrapolated to
umor-bearing individuals.
Besides the effect of MTX and cancer on hippocampal cell pro-
iferation, we also explored the effect on body weight gain and
ickness behavior. The tumor-bearing animals in our study showed
[
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clear signs of cancer cachexia, which can be seen in the arrest or
lowering of bodyweight gainwhile food intake remained stable but
at a lower level compared to control animals. Anorexia cachexia is
a phenomenon frequently observed in cancer patients and is asso-
ciated with the early stages of the disease, serving as a diagnosis
tool, as well as with the terminal stages of cancer. This side effect
of cancer is described as both the loss of adipose tissue and skeletal
muscle mass resulting in a high co-morbidity factor in patients.
Anorexia cachexia induces metabolic changes as well, such as
altered carbohydrate and protein metabolism [24]. This anorexia
cachexia is, however, not related to sickness behavior since cancer
cachexia did not coincidewith an increase in pica behavior. Neither
did MTX induce sickness behavior. MTX did reduce food intake but
this was caused by diarrhea as a consequence of damage to the
cells of the intestinal tract which is a side effect of MTX [7,10]. Pica
behavior after MTX is also not described in the literature although
other cytostatics are associated with this sickness behavior. Cis-
platin is especially known to induce pica behavior [2,4,5,19,30],
but also cyclophosphamide, actinomycin D, and 5-ﬂuorouracil are
associated with sickness behavior [30].
In general, we can conclude that animals treated with MTX
showed a decrease in hippocampal cell proliferation, which possi-
bly contributes to the cognitive impairment seen in some cancer
patients after adjuvant chemotherapy. Since we did not ﬁnd an
interaction effect between MTX and cancer on hippocampal cell
proliferation, our animal model in which we treat healthy animals
with MTX is a validated model to test potential mechanisms that
may contribute to the cognitive impairment seen after adjuvant
chemotherapy treatment.
Conﬂicts of interest
The authors declare that they have no competing ﬁnancial inter-
ests.
Acknowledgments
These studies were ﬁnancially supported by grants from the
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
the Gratema Foundation, and from the René Vogels scholarship.
References
[1] C.M. Bender, S.M. Sereika, S.L. Berga, V.G. Vogel, A.M. Brufsky, K.K. Paraska, C.M.
Ryan, Cognitive impairment associated with adjuvant therapy in breast cancer,
Psychooncology 15 (2006) 422–430.
[2] P.A. Cabezos, G. Vera,M. Castillo, R. Fernandez-Pujol,M.I.Martin, R. Abalo, Radi-
ological study of gastrointestinal motor activity after acute cisplatin in the rat.
Temporal relationship with pica, Auton. Neurosci. 141 (2008) 54–65.
[3] D.D. Correa, T.A. Ahles, Neurocognitive changes in cancer survivors, Cancer J.
14 (2008) 396–400.
[4] B.C. De Jonghe, C.C. Horn, Chemotherapy-induced pica and anorexia are
reduced by common hepatic branch vagotomy in the rat, Am. J. Physiol. Regul.
Integr. Comp. Physiol. 294 (2008) R756–R765.
[5] B.C. De Jonghe, M.P. Lawler, C.C. Horn, M.G. Tordoff, Pica as an adaptive
response: kaolin consumption helps rats recover from chemotherapy-induced
illness, Physiol. Behav. 97 (2009) 87–90.
[6] J.J. Foley, R.B. Raffa, E.A. Walker, Effects of chemotherapeutic agents 5-
ﬂuorouracil and methotrexate alone and combined in a mouse model of
learning and memory, Psychopharmacology (Berl.) 199 (2008) 527–538.
[7] L. Genestier, R. Paillot, L. Quemeneur, K. Izeradjene, J.P. Revillard, Mechanisms
of action of methotrexate, Immunopharmacology 47 (2000) 247–257.
[8] E. Gould, A. Beylin, P. Tanapat, A. Reeves, T.J. Shors, Learning enhances adult
neurogenesis in the hippocampal formation, Nat. Neurosci. 2 (1999) 260–265.
[9] K. Hermelink, M. Untch, M.P. Lux, R. Kreienberg, T. Beck, I. Bauerfeind, K. Mun-
zel, Cognitive function during neoadjuvant chemotherapy for breast cancer:
results of a prospective, multicenter, longitudinal study, Cancer 109 (2007)
1905–1913.
10] F.M. Huennekens, The methotrexate story: a paradigm for development of
cancer chemotherapeutic agents, Adv. Enzyme Regul. 34 (1994) 397–419.
11] N. Kee, S. Sivalingam, R. Boonstra, J.M. Wojtowicz, The utility of Ki-67 and BrdU



















[76 R. Seigers et al. / Brain Rese
12] G. Kempermann, Why new neurons? Possible functions for adult hippocampal
neurogenesis, J. Neurosci. 22 (2002) 635–638.
13] G. Kempermann, L. Wiskott, F.H. Gage, Functional signiﬁcance of adult neuro-
genesis, Curr. Opin. Neurobiol. 14 (2004) 186–191.
14] G.W. Konat,M. Kraszpulski, I. James, H.T. Zhang, J. Abraham, Cognitive dysfunc-
tion induced by chronic administration of common cancer chemotherapeutics
in rats, Metab. Brain Dis. 23 (2008) 325–333.
15] M. Krajinovic, A. Moghrabi, Pharmacogenetics of methotrexate, Pharmacoge-
nomics 5 (2004) 819–834.
16] B.P. Kreukels, S.B. Schagen, K.R. Ridderinkhof, W. Boogerd, H.L. Hamburger, F.S.
van Dam, Electrophysiological correlates of information processing in breast-
cancer patients treated with adjuvant chemotherapy, Breast Cancer Res. Treat.
94 (2005) 53–61.
17] B.N. Lee, R. Dantzer, K.E. Langley, G.J. Bennett, P.M. Dougherty, A.J. Dunn,
C.A. Meyers, A.H. Miller, R. Payne, J.M. Reuben, X.S. Wang, C.S. Cleeland, A
cytokine-based neuroimmunologic mechanism of cancer-related symptoms,
Neuroimmunomodulation 11 (2004) 279–292.
18] J.E. Macleod, J.A. DeLeo, W.F. Hickey, T.A. Ahles, A.J. Saykin, D.J. Bucci, Cancer
chemotherapy impairs contextual but not cue-speciﬁc fear memory, Behav.
Brain Res. 181 (2007) 168–172.
19] N.M. Malik, Y.L. Liu, N. Cole, G.J. Sanger, P.L. Andrews, Differential effects
of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist
(GR205171) on cisplatin-induced changes in behaviour, food intake, pica and
gastric function in rats, Eur. J. Pharmacol. 555 (2007) 164–173.
20] S.B. Schagen, M.J. Muller, W. Boogerd, G.J. Mellenbergh, F.S. van Dam, Change
in cognitive function after chemotherapy: a prospective longitudinal study in
breast cancer patients, J. Natl. Cancer Inst. 98 (2006) 1742–1745.
21] R. Seigers, S.B. Schagen, W. Beerling, W. Boogerd, O. van Tellingen, F.S. van
Dam, J.M. Koolhaas, B. Buwalda, Long-lasting suppression of hippocampal cell
[
[ulletin 81 (2010) 472–476
proliferation and impaired cognitive performance by methotrexate in the rat,
Behav. Brain Res. 186 (2008) 168–175.
22] R. Seigers, S.B. Schagen, C.M. Coppens, P.J. van der Most, F.S. van Dam,
J.M. Koolhaas, B. Buwalda, Methotrexate decreases hippocampal cell pro-
liferation and induces memory deﬁcits in rats, Behav. Brain Res. 2 (2009)
279–284.
23] V. Shilling, V. Jenkins, Self-reported cognitive problems in women receiving
adjuvant therapy for breast cancer, Eur. J. Oncol. Nurs. 11 (2007) 6–15.
24] M.J. Tisdale, Cachexia in cancer patients, Nat. Rev. Cancer 2 (2002)
862–871.
25] G. Vera, A. Chiarlone, M.I. Martin, R. Abalo, Altered feeding behaviour
induced by long-term cisplatin in rats, Auton. Neurosci. 126–127 (2006)
81–92.
26] J.S. Wefel, R. Lenzi, R.L. Theriault, R.N. Davis, C.A. Meyers, The cognitive seque-
lae of standard-dose adjuvant chemotherapy inwomenwith breast carcinoma:
results of a prospective, randomized, longitudinal trial, Cancer 100 (2004)
2292–2299.
27] J.S. Wefel, R. Lenzi, R. Theriault, A.U. Buzdar, S. Cruickshank, C.A. Meyers,
‘Chemobrain’ in breast carcinoma?: a prologue, Cancer 101 (2004) 466–
475.
28] J.S. Wefel, M.E. Witgert, C.A. Meyers, Neuropsychological sequelae of non-
central nervous system cancer and cancer therapy, Neuropsychol. Rev. 18
(2008) 121–131.29] G. Winocur, J. Vardy, M.A. Binns, L. Kerr, I. Tannock, The effects of the anti-
cancer drugs, methotrexate and 5-ﬂuorouracil, on cognitive function in mice,
Pharmacol. Biochem. Behav. 85 (2006) 66–75.
30] K. Yamamoto, M. Nakai, K. Nohara, A. Yamatodani, The anti-cancer drug-
induced pica in rats is related to their clinical emetogenic potential, Eur. J.
Pharmacol. 554 (2007) 34–39.
